cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol | 869006-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol
• 英文别名: 4-[(1R,2S)-6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenol
• CAS: 869006-55-3
• 化学式: C₂₃H₂₂O₂
• 分子量: 330.426
• InChiKey: KUALGQALXWQQPQ-GGAORHGYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol 在 盐酸 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (5R,6S)-5-{4-[2-((R)-3-Methyl-pyrrolidin-1-yl)-ethoxy]-phenyl}-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-ol
  参考文献：
  名称：

  Estrogen receptor ligands. Part 14: Application of novel antagonist side chains to existing platforms

  摘要：

  Two novel side chains which had previously been found to enhance antagonist activity in the dihydrobenzoxathiin SERM series were applied to three existing platforms. The novel side chains did not improve the antagonist activity of the existing platforms. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.084
• 作为产物：
  描述：

  magnesium,phenylmethoxybenzene,bromide 在 palladium dihydroxide 四(三苯基膦)钯 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 cis-4-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthalenyl)phenol
  参考文献：
  名称：

  Estrogen receptor ligands. Part 14: Application of novel antagonist side chains to existing platforms

  摘要：

  Two novel side chains which had previously been found to enhance antagonist activity in the dihydrobenzoxathiin SERM series were applied to three existing platforms. The novel side chains did not improve the antagonist activity of the existing platforms. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.084

文献信息

• TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20170129855A1

  公开（公告）日：2017-05-11

  Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本发明描述了具有雌激素受体调节活性的四氢萘化合物，其具有如下结构式I： 及其立体异构体、互变异构体或药用可接受盐，以及所描述的取代基和结构特征。还描述了包括结构式I化合物的药物组合物和药品，以及使用这类雌激素受体调节剂的方法，单独使用或与其他治疗剂联合使用，用于治疗通过雌激素受体介导或依赖的疾病或状况。
• [EN] ESTROGEN RECEPTOR TARGETING ANTAGONISTS<br/>[FR] ANTAGONISTES CIBLANT LE RÉCEPTEUR DES OESTROGÈNES
  申请人：XAVIER UNIV OF LOUISIANA

  公开号：WO2020055973A1

  公开（公告）日：2020-03-19

  The present disclosure relates to compounds that act as antagonists via binding to the ER ligand binding domain non-covalently or covalently, or act as both antagonists and ER protein degraders, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.

  本公开涉及通过非共价或共价结合到ER配体结合结构域的化合物，作为拮抗剂或同时作为拮抗剂和ER蛋白降解剂，并且涉及这些化合物的合成。此外，本公开教导了利用这些化合物治疗增殖性疾病，包括癌症，特别是乳腺癌，尤其是ER+乳腺癌。
• METHOD FOR THE PREPARATION OF LASOFOXIFENE
  申请人：Lustig Petr

  公开号：US20100256394A1

  公开（公告）日：2010-10-07

  A method of preparing (−)-cis-(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate-lasofoxifene of formula 1, comprising the following steps a) Preparation of cis-1-2-[4-(2-phenyl-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-phenoxy]ethyl}pyrrolidine of formula (3) by alkylation of cis-1-(4-hydroxyphenyl)-2-phenyl-6-methoxy-1,2,3,4-tetrahydronaphthalene with 1-(2-chloroethyl)pyrrolidine base or its salt, b) Deprotection of the hydroxyl group in the substance of formula (3) by the effect of hydrobromic acid generating cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide of formula (2a), c) Conversion of the substance of formula (2a) into cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol of formula (2b), d) Preparation of lasofoxifene of formula (1) by conversion into the corresponding diasteroisomer by reaction with D-tartaric acid and crystallization.

  制备(−)-顺式-(5R,6S)-6-苯基-5-[4-(2-吡咯烷-1-基乙氧)苯基]-5,6,7,8-四氢萘-2-醇D-酒石酸盐-拉索福辛的方法，包括以下步骤：a）通过将顺式-1-2-[4-(2-苯基-6-甲氧基-1,2,3,4-四氢萘-1-基)-苯氧基]乙基}吡咯烷的式（3）与1-(2-氯乙基)吡咯烷碱或其盐烷基化，制备式（3）的化合物；b）通过氢溴酸作用去保护式（3）中的羟基，生成式（2a）的顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧)苯基]-5,6,7,8-四氢萘-2-醇氢溴酸盐；c）将式（2a）的化合物转化为式（2b）的顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧)苯基]-5,6,7,8-四氢萘-2-醇；d）通过与D-酒石酸反应并结晶，将化合物转化为相应的对映异构体，制备式（1）的拉索福辛。
• Tetrahydronaphthalene estrogen receptor modulators and uses thereof
  申请人：Genentech, Inc.

  公开号：US10399939B2

  公开（公告）日：2019-09-03

  Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述的是具有雌激素受体调节活性或功能的四氢萘化合物，其结构如式 I 所示： 及其立体异构体、同系物或药学上可接受的盐，并具有本文所述的取代基和结构特征。还描述了包括式 I 化合物的药物组合物和药物，以及单独或与其他治疗剂联合使用此类雌激素受体调节剂治疗由雌激素受体介导或依赖于雌激素受体的疾病或病症的方法。
• Chem. Lett. 2011, 40, 1272-1274
  作者：

  DOI：——

  日期：——